GM
MLYS icon

GeoWealth Management’s Mineralys Therapeutics MLYS Stock Holding History

GeoWealth Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,439
Closed -$17.7K – 1516
2024
Q4 		$17.7K Hold
1,439
– – ﹤0.01% 1400
2024
Q3 		$17.4K Buy
+1,439
New +$17.4K ﹤0.01% 1305

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GeoWealth Management's MLYS Position: Q1 2025 in Review

GeoWealth Management sold out of Mineralys Therapeutics (MLYS) in Q1 2025, closing a stake of 1,439 shares — an estimated $17.7K sold.

GeoWealth Management first reported a position in MLYS in Q3 2024 and held it in 2 quarters. The position peaked at $17.7K in Q4 2024. 149 funds tracked by Wall St. Rank hold MLYS as of Q1 2025.

  • GeoWealth Management reported no remaining Mineralys Therapeutics position as of Q1 2025 after selling out during the quarter.
  • GeoWealth Management sold 1,439 Mineralys Therapeutics shares in Q1 2025, an estimated $17.7K.
  • GeoWealth Management first reported a position in Mineralys Therapeutics in Q3 2024 and held it in 2 quarters.
  • GeoWealth Management's Mineralys Therapeutics position peaked at $17.7K in Q4 2024.
  • 149 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2025.

Based on GeoWealth Management's 13F filing for Q1 2025, filed 9 May 2025.